JUN 23, 2019 8:32 AM PDT

FDA Approves Vyleesi - "The Female Viagra" for Premenopausal Women

WRITTEN BY: Tiffany Dazet

Last Friday, the FDA approved a new drug that some are referring to as “the female Viagra.” Vyleesi, the drug’s market name, is injectable bremelanotide intended to restore natural sexual desire in premenopausal women suffering from hypoactive sexual desire disorder (HSDD). Vyleesi is the second FDA-approved treatment for female HSDD. Addyi, the other drug approved for HSDD in 2015, is a pill that must be taken daily and restricts alcohol use, whereas Vyleesi is administered as needed and does not restrict alcohol use.

According to AMAG Pharmaceuticals, the U.S. sponsor of the drug, approximately six million premenopausal women in the United States suffer from HSDD. The FDA defines HSDD as “low sexual desire that causes marked distress or interpersonal difficulty.” Underlying medical or psychiatric conditions, relationship problems, or other drug substances do not cause HSDD. In a statement from the FDA, Dr. Hylton V. Joffe—director of the Center for Drug Evaluation and Research’s Division of Bone, Reproductive, and Urologic products—stated “there are women who, for no known reason, have reduced sexual desire that causes marked distress, and who can benefit from safe and effective pharmacologic treatment.”

Vyleesi operates by activating melanocortin receptors, a brain-stimulating hormone associated with sexual arousal in both men and women. The medication is injected under abdomen or thigh skin 45-minutes before sexual activity. Patients are instructed only to use one dose within 24 hours, and no more than eight doses per month.

Two 24-week safety and effectiveness trials included 1,247 premenopausal women with generalized HSDD. Common side effects of Vyleesi are nausea and vomiting, flushing, injection site reactions, and headache. In clinical trials, approximately 40% of participants experienced nausea. Because Vyleesi increases blood pressure after injecting, patients with high blood pressure or cardiovascular disease are warned not to use the drug.

AMAG Pharmaceuticals estimates that Vyleesi will be available in September through select pharmacies. Prior to the FDA’s approval, AMAG launched a campaign to increase awareness and end stigma about female HSDD. The key message of this campaign—called “unblush”—is that “HSDD can be caused by an imbalance of certain hormones and neurotransmitters in the brain, a surmise drawn from functional MRI scans of women with varying levels of sexual desire. If the basis of the condition is physiological, so too may be the fix.”

Sources: FDA, AMAG, LA Times, Photo via AP News

Resources: Queen V - Livin' Libido Loca

About the Author
  • Tiffany grew up in Southern California, where she attended San Diego State University. She graduated with a degree in Biology with a marine emphasis, thanks to her love of the ocean and wildlife. With 13 years of science writing under her belt, she now works as a freelance writer in the Pacific Northwest.
You May Also Like
DEC 23, 2020
Immunology
COVID Survivors Stay Immune for at Least a Year
DEC 23, 2020
COVID Survivors Stay Immune for at Least a Year
Once the coronavirus enters the body, the immune system springs into action, producing antibodies that bind to and neutr ...
JAN 06, 2021
Immunology
Probiotic Boosters Are Lifesavers for Preterm Babies
JAN 06, 2021
Probiotic Boosters Are Lifesavers for Preterm Babies
When administered shortly after birth, a recent study has found that the supplementation combo of probiotics and prebiot ...
JAN 03, 2021
Cannabis Sciences
Cannabis Users Don't Understand Health Risks of Smoking, Study Finds
JAN 03, 2021
Cannabis Users Don't Understand Health Risks of Smoking, Study Finds
A recent study has found that cannabis users often classify themselves as 'non-smokers' even though they smoke c ...
JAN 04, 2021
Microbiology
Some Microbes Could Help Treat Type 2 Diabetes
JAN 04, 2021
Some Microbes Could Help Treat Type 2 Diabetes
The microbial community in our gastrointestinal tract has been shown to have a significant impact on our health and well ...
JAN 14, 2021
Clinical & Molecular DX
Tip of the Iceberg: Inaccuracies in Prostate Cancer Diagnostics
JAN 14, 2021
Tip of the Iceberg: Inaccuracies in Prostate Cancer Diagnostics
  Only 10 percent of icebergs are visible on the surface of the water; the remaining 90 percent remains submerged. ...
JAN 17, 2021
Genetics & Genomics
New Insights Into Kabuki Syndrome
JAN 17, 2021
New Insights Into Kabuki Syndrome
Kabuki syndrome is a rare multisystemic disorder that causes delays in growth, distinctive facial features, short statur ...
Loading Comments...